Signaturefd, LLC Viking Therapeutics, Inc. Transaction History

Signaturefd, LLC

$5.2 Billion
Q3 2024

A detailed history of Signaturefd, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 1,351 shares of VKTX stock, worth $69,617. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,351

Previous 1,163 16.17%

Holding current value

$69,617

Previous $61,000 39.34%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	BUY	$49.84 - $70.47 $9,369 - $13,248	188 Added 16.17%	1,351 $85,000
Q2 2024 Jul 29, 2024	SELL	$47.39 - $80.2 $13,695 - $23,177	-289 Reduced 19.9%	1,163 $61,000
Q1 2024 May 03, 2024	BUY	$17.4 - $94.5 $8,717 - $47,344	501 Added 52.68%	1,452 $119,000
Q4 2023 Jan 31, 2024	SELL	$9.24 - $19.64 $4,712 - $10,016	-510 Reduced 34.91%	951 $17,000
Q1 2023 Apr 28, 2023	SELL	$8.08 - $17.33 $8,395 - $18,005	-1,039 Reduced 41.56%	1,461 $24,000
Q3 2022 Nov 08, 2022	BUY	$2.55 - $3.89 $6,375 - $9,725	2,500 New	2,500 $7,000
Q3 2021 Oct 28, 2021	SELL	$5.58 - $7.04 $1,065 - $1,344	-191 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$5.3 - $6.71 $1,012 - $1,281	191 New	191 $1,000
Q2 2020 Jul 30, 2020	SELL	$4.35 - $8.08 $8 - $16	-2 Closed	0 $0
Q4 2019 Feb 05, 2020	SELL	$6.38 - $8.73 $638 - $873	-100 Reduced 98.04%	2 $0
Q2 2019 Jul 31, 2019	SELL	$7.67 - $10.63 $7 - $10	-1 Reduced 0.97%	102 $1,000
Q1 2019 May 09, 2019	SELL	$7.58 - $9.94 $3,767 - $4,940	-497 Reduced 82.83%	103 $1,000
Q4 2018 Feb 13, 2019	BUY	$7.16 - $16.21 $3,580 - $8,105	500 Added 500.0%	600 $5,000
Q2 2018 Aug 14, 2018	BUY	$3.88 - $12.74 $388 - $1,274	100 New	100 $1,000

Others Institutions Holding VKTX

# of Institutions

473

Shares Held

66.2M

Call Options Held

5.72M

Put Options Held

3.39M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.95B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account